• Flash Pack

  Participated · Equity · Oct 2023

  Flash Pack designs boutique adventure trips for solo travelers in their 30s and 40s, creating experiences that would be difficult or too expensive to arrange alone. Each trip is built to foster group dynamics and bring together like-minded people at the same life stage. The company is based in New York City and was founded by Lee Thompson and Radha Vyas. In October 2023 Flash Pack raised $6.2M in funding. The firm intends to use the proceeds to bolster its product and platform, hire in technology roles, and scale across the U.S.

• NBE-Therapeutics

  Participated · Series B · Jun 2018

  NBE-Therapeutics develops next-generation immune-stimulatory antibody drug conjugates (iADC™) to improve treatment options for cancer patients. The company leverages proprietary platforms including Transpo-mAb Display™ for antibody discovery, SMAC-Technology™ for site-specific payload conjugation, and an immune-stimulatory anthracycline-based toxin platform. Led by CEO and founder Dr. Ulf Grawunder, NBE advances its products toward clinical proof of concept. The company recently completed a USD 22M Series C financing to fund near-term development. Proceeds will be used to advance the lead asset NBE-002 through early clinical trials and to strengthen the development team, management and board. The business is headquartered in Basel, Switzerland. NBE Therapeutics develops antibody-drug conjugates (ADCs) based on its proprietary site-specific SMAC-conjugation™ technology and a novel anthracycline-based toxin platform. The company is advancing a lead program, NBE-002, which targets ROR-1 primarily for the treatment of solid tumors. NBE plans to use recent financing to move NBE-002 into clinical development and to advance additional ADC pipeline programs through early development. The company is led by CEO Dr. Ulf Grawunder and Chairman Theo Walthie. NBE Therapeutics is based in Basel, Switzerland. The firm aims to develop ADC product candidates against tumor targets in indications of high unmet medical need. NBE-Therapeutics develops antibody-drug conjugates (ADCs) and proprietary platform technologies for ADC discovery and payload conjugation. The company leverages Transpo-mAb DisplayTM for antibody discovery, patent-pending SMAC-TechnologyTM for site-specific payload conjugation, and an ultra-potent anthracycline-based toxin platform. Founded in 2012 and led by CEO Dr. Ulf Grawunder, NBE is advancing a lead ADC product through clinical development. It plans to use the new funding to push the lead product to the end of phase I/II clinical trials and to further develop its platforms. The company is based in Basel, Switzerland and focuses on therapies to improve outcomes for cancer patients. NBE-Therapeutics is a biotech company developing next‑generation antibody–drug conjugate (ADC) product candidates using proprietary antibody discovery and enzymatic conjugation technologies. It has fully validated its SMAC-Technology enzymatic antibody-payload conjugation platform and its Transpo-mAb antibody discovery and engineering platform, the latter recently granted European patent EP2692865B1. The company completed a number of technology validation milestones during its first 2.5 years of operations since incorporation in mid‑2012 and now plans to leverage those platforms to develop a portfolio of clinical ADC development candidates. NBE-Therapeutics has collaborations with academic partners including ETH Zürich, University Hospital Basel and the Technical University for Life Sciences North‑Western Switzerland. Financially, it raised CHF 2.5 million in seed funding during its first 2.5 years and has now added CHF 3.0 million in new working capital from a Series A capital increase, bringing investor funding to CHF 5.5 million. These investor funds are complemented by CHF 4.0 million in research grants from academic collaborations and an FP7 "Research for SMEs" EU grant. The company intends to use the new funds to advance its ADC development programs toward clinical validation in cancer patients. NBE-Therapeutics AG, founded in 2012 and based in Basel, focuses on the development of antibody-drug conjugates (ADCs) for cancer treatment. The company has built the Transpo-mAb fully human antibody discovery platform and the SMAC-Technology enzymatic payload conjugation platform, which has been validated in proof-of-concept studies. Its core product approach is generating homogeneous next-generation ADCs that conjugate highly potent cellular toxins to cancer-specific antibodies for targeted destruction of cancer cells. NBE-Therapeutics is pursuing translational collaborations to evaluate combinations of its ADCs with other immune-therapeutic interventions. Recently the company secured a CHF 600K transfer-project grant to support a collaborative program studying synergies between its ADCs and immunotherapies with academic partners.

No current team members are available.